BACKGROUND AND OBJECTIVE

To assess the dosimetric feasibility of a stereotactic body radiotherapy (SBRT) dose escalated protocol, with a simultaneous integrated boost (SIB) and a simultaneous integrated protection (SIP) approach, in patients with locally advanced pancreatic cancer (LAPC).

MATERIAL AND METHODS

Twenty LAPC lesions, previously treated with SBRT at our Institution, were re-planned. The original prescribed and administered dose was 50/30/25 Gy in five fractions to PTV (tumor-vessel interface [TVI])/PTV (tumor volume)/PTV (overlap area between PTV and planning organs at risk volume [PRV]), respectively. At re-planning, the prescribed dose was escalated up to 60/40/33 Gy in five fractions to PTV/PTV/PTV, respectively. All plans were performed using an inspiration breath hold (IBH) technique and generated with volumetric modulated arc therapy (VMAT). Well-established and accepted OAR dose constraints were used (D < 33 Gy for luminal OARs and D < 38 Gy for corresponding PRV). The primary end-point was to achieve a median dose equal to the prescription dose for the PTV with D≥ 95% (95% of prescription dose is the minimum dose), and a coverage for PTV and PTV of D≥95%, with minor deviations in OAR dose constraints in < 10% of the plans.

RESULTS

PTV median (± SD) dose/D/conformity index (CI) were 60.54 (± 0.85) Gy/58.96 (± 0.86) Gy/0.99 (± 0.01), respectively; whilst PTV median (± SD) dose/D were 44.51 (± 2.69) Gy/38.44 (± 0.82) Gy, and PTV median (± SD) dose/D were 35.18 (± 1.42) Gy/33.01 (± 0.84) Gy, respectively. With regard to OARs, median (± SD) maximum dose (D) to duodenum/stomach/bowel was 29.31 (± 5.72) Gy/25.29 (± 6.90) Gy/27.03 (± 5.67) Gy, respectively. A minor acceptable deviation was found for a single plan (bowel and duodenum D=34.8 Gy). V38 < 0.5 cc was achieved for all PRV luminal OARs.

CONCLUSIONS

In LAPC patients SBRT, with a SIB/SIP dose escalation approach up to 60/40/33 Gy in five fractions to PTV/PTV/PTV, respectively, is dosimetrically feasible with adequate PTVs coverage and respect for OAR dose constraints.